In a study that included nearly 30,000 women from Nordic countries who had filled a selective serotonin reuptake inhibitor prescription during pregnancy, researchers found no significant association between use of these medications during pregnancy and risk of stillbirth, neonatal death, or postneonatal death, after accounting for factors including maternal psychiatric disease.